Shares of BridgeBio Pharma, Inc. (BBIO) jumped 25% on Monday morning after the U.S. Food and Drug Administration approved Attruby or acoramidis for the treatment of adults with Transthyretin amyloid cardiomyopathy (ATTR-CM) to reduce cardiovascular death and hospitalization.
BBIO is currently trading at $29.46, up $6.04 or 25.79%, on the Nasdaq. The stock opened its trading at $28.80 after closing Friday at $23.42. The stock has traded between $21.62 and $44.32 in the past 52-week period.
FDA's approval came through late Friday. The approval is based on positive results seen in the ATTRibute-CM Phase 3 study, where Attruby significantly reduced death and cardiovascular-related hospitalization, and improved quality of life.
BridgeBio has submitted a Marketing Authorization Application to the European Medicines Agency, with a decision expected in 2025. BridgeBio has granted exclusive rights to Bayer to commercialize acoramidis for ATTR-CM in Europe.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.